Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912663 · ClinicalTrials.gov registry record · Phase 1
Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.
A Phase 1 study, sponsored by Justin Fraser.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02912663: Completed Phase 1 study, sponsored by Justin Fraser.
NCT02912663 is a Phase 1 study that has completed, run by Justin Fraser. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02912663, a Phase 1 study, has completed, sponsored by Justin Fraser.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a phase 1, blinded-outcome, randomized, placebo controlled study to investigate the safety and feasibility of super-selective intra-arterial administration of verapamil and magnesium sulfate immediately following successful endovascular thrombectomy as a potential neuroprotective synergistic therapeutic strategy in emergent large vessel occlusion stroke. This trial represents the first time that magnesium sulfate will be evaluated in human subjects as a superselectively administered neuroprotective agent administered in an acute time frame as an adjunct to intra-arterial thrombectomy. Furthermore, it will represent the first trial to evaluate combinational therapy for acute stroke neuroprotection.
Primary Outcome
Defined as a hemorrhage occurring within 48 hours after study inclusion, temporally related to the intervention, and occurring with worsening neurological status as documented in the clinical exam.
Interventions
- OTHER Placebo
- DRUG Verapamil and Magnesium Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2020-01-14 |
| Phase | Phase 1 |
What the finished NCT02912663 record still lists
NCT02912663 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02912663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02912663 about?
NCT02912663 is a clinical study titled "Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.". This is a phase 1, blinded-outcome, randomized, placebo controlled study to investigate the safety and feasibility of super-selective intra-arterial administration of verapamil and magnesium sulfate immediately following successful endovascular thrombectomy as a potential neuroprotective synergistic...
What is the current status of trial NCT02912663?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-10-11. Estimated completion is 2020-01-14.
What interventions are being tested in trial NCT02912663?
The interventions under investigation include: Placebo (OTHER), Verapamil and Magnesium Sulfate (DRUG).
Who is sponsoring clinical trial NCT02912663?
This trial is sponsored by Justin Fraser, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02912663's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI